Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
12 8월 2021 - 5:05AM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
financial results for the second quarter ended June 30, 2021, and
provided an overview of recent developments.
“We recently announced initial summary data from the dose
escalation portion of the Phase 1b trial evaluating ATRC-101 in
multiple solid tumors,” said John Orwin, Chief Executive Officer.
“ATRC-101 was well-tolerated in the study, and we believe that the
initial signs of activity, which were associated with expression of
ATRC-101’s target, provide strong rationale for further evaluation.
Additionally, we believe the data provide validation of the ability
of our discovery platform to identify druggable tumor targets
shared across broad groups of patients. We look forward to
providing an update on our early-stage pipeline in the coming
months as well as reporting additional monotherapy in 1H22,
pembrolizumab combination data in mid-2022, and chemotherapy
combination data in late 2022.”
Recent Developments and Highlights
- Atreca announced initial summary
data from the dose escalation portion of the Phase 1b trial of
ATRC-101 in multiple solid tumors. ATRC-101 was well-tolerated with
no dose-limiting toxicities observed. Eight of the 20 participants
(40%) evaluable prior to the data cut-off in this analysis
experienced stable disease (SD) as their best RECIST response,
including four with tumor size reduction. The disease control
observed in the study was associated with ATRC-101 target
expression, and preliminary biomarker analysis was consistent with
the proposed mechanism of action for ATRC-101.The peak
concentration of ATRC-101 was dose proportional and minimal
accumulation was observed following multiple doses.
- Phase 1b monotherapy dose expansion
of ATRC-101 is ongoing at 30 mg/kg. A combination study evaluating
ATRC-101 with pembrolizumab is active and another combination study
with pegylated liposomal doxorubicin is expected to begin enrolling
patients in 4Q21. Atreca expects to report additional monotherapy
data in 1H22, pembrolizumab combination data in mid-2022 and
chemotherapy combination data in late 2022.
- Supported by data from the dose
escalation portion of the trial, Atreca is developing a diagnostic
to enable prospective patient selection based on target
expression.
Second Quarter 2021 Financial Results
- As of June 30, 2021, cash and cash equivalents and short-term
investments totaled $182.3 million.
- Research and development expenses for the three months ended
June 30, 2021 were $19.0 million, including non-cash share-based
compensation expense of $1.9 million.
- General and administrative expenses for the three months ended
June 30, 2021 were $8.0 million, including non-cash share-based
compensation expense of $2.0 million.
- Atreca reported a net loss of $26.7 million, or basic and
diluted net loss per share attributable to common stockholders of
$0.72, for the three months ended June 30, 2021.
About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel
antibody-based immunotherapeutics generated by its differentiated
discovery platform. Atreca’s platform allows access to an
unexplored landscape in oncology through the identification of
unique antibody-target pairs generated by the human immune system
during an active immune response against tumors. These antibodies
provide the basis for first-in-class therapeutic candidates, such
as our lead product candidate ATRC-101. A Phase 1b study evaluating
ATRC-101 in multiple solid tumor cancers is currently enrolling
patients. For more information on Atreca, please visit
www.atreca.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include, but are not
limited to, statements about our plans, objectives, representations
and contentions and typically are identified by use of terms such
as “continued,” “anticipate,” “potential,” “expect,” “believe,”
“planned,” and similar words, although some forward-looking
statements are expressed differently. These statements include
those related to our strategy and future plans, including
statements regarding the development of ATRC-101 and our
preclinical, clinical and regulatory plans and the timing thereof,
the availability and timing of data from the monotherapy dose
escalation portions of the Phase 1b trial and from combinations
evaluating ATRC-101 with pembrolizumab and with chemotherapy, and
our development of a diagnostic to enable prospective patient
selection based on target expression. Our actual results may differ
materially from those indicated in these forward-looking statements
due to risks and uncertainties related to the initiation, timing,
progress and results of our research and development programs,
preclinical studies, clinical trials, regulatory submissions, and
other matters that are described in our filings with the Securities
and Exchange Commission (SEC) and available on the SEC’s website
at www.sec.gov, including in the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” sections of our most recently filed annual
report on Form 10-K and quarterly report on Form 10-Q. Investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release,
and we undertake no obligation to update any forward-looking
statement in this press release, except as required by law.
Atreca, Inc.Condensed
Consolidated Balance Sheets(in thousands, except share and
per share data)
|
|
|
|
|
|
|
June
30, |
|
December
31, |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
(unaudited) |
|
|
ASSETS |
|
|
|
|
|
|
|
|
|
Current
Assets |
Cash and
cash equivalents |
|
$ |
93,603 |
|
|
$ |
60,789 |
|
Investments |
|
|
88,708 |
|
|
|
179,296 |
|
Prepaid
expenses and other current assets |
|
|
10,579 |
|
|
|
9,037 |
|
Total current assets |
|
|
192,890 |
|
|
|
249,122 |
|
Property and
equipment, net |
|
|
45,099 |
|
|
|
19,831 |
|
Deposits and
other |
|
|
2,852 |
|
|
|
3,111 |
|
Total assets |
|
$ |
240,841 |
|
|
$ |
272,064 |
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
Current
Liabilities |
Accounts
payable |
|
$ |
3,596 |
|
|
$ |
5,216 |
|
Accrued
expenses |
|
|
8,633 |
|
|
|
10,302 |
|
Other
current liabilities |
|
|
2,078 |
|
|
|
1,900 |
|
Total current liabilities |
|
|
14,307 |
|
|
|
17,418 |
|
Capital
lease obligations, net of current portion |
|
|
- |
|
|
|
4 |
|
Deferred
rent |
|
|
27,931 |
|
|
|
12,585 |
|
Total liabilities |
|
|
42,238 |
|
|
|
30,007 |
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ equity |
Common
stock |
|
|
4 |
|
|
|
4 |
|
Additional
paid-in capital |
|
|
501,474 |
|
|
|
492,436 |
|
Accumulated
other comprehensive income |
|
|
16 |
|
|
|
58 |
|
Accumulated
deficit |
|
|
(302,891 |
) |
|
|
(250,441 |
) |
Total stockholders’ equity |
|
|
198,603 |
|
|
|
242,057 |
|
Total liabilities and stockholders’ equity |
|
$ |
240,841 |
|
|
$ |
272,064 |
|
|
|
|
|
|
Atreca, Inc.Condensed
Consolidated Statements of Operations(in thousands, except
share and per share data)(unaudited)
($ amounts in 000's, except per share amounts) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months
Ended |
|
Six Months
Ended |
|
|
|
June 30, |
|
June 30, |
|
|
|
|
2021 |
|
|
|
2020 |
|
|
|
2021 |
|
|
|
2020 |
|
|
|
|
|
|
|
|
|
|
|
Expenses |
|
|
|
|
|
|
|
|
|
Research and
development |
|
$ |
19,036 |
|
|
$ |
14,180 |
|
|
$ |
37,424 |
|
|
$ |
28,390 |
|
|
General and
administrative |
|
|
8,031 |
|
|
|
6,458 |
|
|
|
15,852 |
|
|
|
13,581 |
|
|
Total
expenses |
|
|
27,067 |
|
|
|
20,638 |
|
|
|
53,276 |
|
|
|
41,971 |
|
Interest and other income (expense) |
|
|
|
|
|
|
|
|
|
Other
income |
|
|
349 |
|
|
|
403 |
|
|
|
693 |
|
|
|
634 |
|
|
Interest
income |
|
|
56 |
|
|
|
255 |
|
|
|
147 |
|
|
|
940 |
|
|
Interest
expense |
|
|
(1 |
) |
|
|
(1 |
) |
|
|
(2 |
) |
|
|
(2 |
) |
|
Loss on
disposal of property and equipment |
|
|
(11 |
) |
|
|
- |
|
|
|
(11 |
) |
|
|
- |
|
Loss before Income tax expense |
|
|
(26,674 |
) |
|
|
(19,981 |
) |
|
|
(52,449 |
) |
|
|
(40,399 |
) |
Income tax expense |
|
|
(1 |
) |
|
|
- |
|
|
|
(1 |
) |
|
|
- |
|
Net loss |
|
$ |
(26,675 |
) |
|
$ |
(19,981 |
) |
|
$ |
(52,450 |
) |
|
$ |
(40,399 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.72 |
) |
|
$ |
(0.71 |
) |
|
$ |
(1.42 |
) |
|
$ |
(1.44 |
) |
Weighted-average shares used in computing |
|
|
|
|
|
|
|
|
net loss per share, basic and diluted |
|
|
36,893,827 |
|
|
|
28,144,714 |
|
|
|
36,867,592 |
|
|
|
28,082,930 |
|
|
|
|
|
|
|
|
|
|
|
Contacts
Atreca, Inc.Herb CrossChief Financial
Officerinfo@atreca.comInvestors:Alex Gray,
650-779-9251agray@atreca.com
Media:Sheryl Seapy, 213-262-9390sseapy@w2ogroup.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024